The U.S. Food and Drug Administration has cleared Neuronetics, Inc.’s NeuroStar Transcranial Magnetic Stimulation (TMS) system for treating Major Depressive Disorder in adults whose condition did not improve by the intake of minimally effective dose of an antidepressant. A non-systemic and non-invasive solution for depression, the NeuroStar TMS device delivers magnetic pulses to stimulate nerve cells of that area of the brain which is associated with depression. Patients do not need to be anesthetized and the whole outpatient procedure is over in 40 minutes.